Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 24 entries
Sorted by: Best Match Show Resources per page
Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA.

Annals of the rheumatic diseases

Kissel T, van Wesemael TJ, Lundquist A, Kokkonen H, Kawakami A, Tamai M, van Schaardenburg D, Wuhrer M, Huizinga TW, Scherer HU, van der Woude D, Rantapää-Dahlqvist S, Toes REM.
PMID: 34385139
Ann Rheum Dis. 2021 Aug 12; doi: 10.1136/annrheumdis-2021-220841. Epub 2021 Aug 12.

No abstract available.

Cite
Kissel T, van Wesemael TJ, Lundquist A, et al. Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2021-220841.
Kissel, T., van Wesemael, T. J., Lundquist, A., Kokkonen, H., Kawakami, A., Tamai, M., van Schaardenburg, D., Wuhrer, M., Huizinga, T. W., Scherer, H. U., van der Woude, D., Rantapää-Dahlqvist, S., & Toes, R. E. M. (2021). Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-220841
Kissel, Theresa, et al. "Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2021-220841
Kissel T, van Wesemael TJ, Lundquist A, Kokkonen H, Kawakami A, Tamai M, van Schaardenburg D, Wuhrer M, Huizinga TW, Scherer HU, van der Woude D, Rantapää-Dahlqvist S, Toes REM. Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA. Ann Rheum Dis. 2021 Aug 12; doi: 10.1136/annrheumdis-2021-220841. Epub 2021 Aug 12. PMID: 34385139.
Copy Download .nbib Format: NLM
Correction to: Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the Preclinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort.

Arthritis research & therapy

Costello RE, Humphreys JH, Sergeant JC, Haris M, Stirling F, Raza K, van Schaardenburg D, Bruce IN.
PMID: 34666823
Arthritis Res Ther. 2021 Oct 19;23(1):263. doi: 10.1186/s13075-021-02645-1.

No abstract available.

Cite
Costello RE, Humphreys JH, Sergeant JC, et al. Correction to: Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the Preclinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort. Arthritis Res Ther. 2021;23(1):263doi: 10.1186/s13075-021-02645-1.
Costello, R. E., Humphreys, J. H., Sergeant, J. C., Haris, M., Stirling, F., Raza, K., van Schaardenburg, D., & Bruce, I. N. (2021). Correction to: Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the Preclinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort. Arthritis research & therapy, 23(1), 263. https://doi.org/10.1186/s13075-021-02645-1
Costello, R E, et al. "Correction to: Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the Preclinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort." Arthritis research & therapy vol. 23,1 (2021): 263. doi: https://doi.org/10.1186/s13075-021-02645-1
Costello RE, Humphreys JH, Sergeant JC, Haris M, Stirling F, Raza K, van Schaardenburg D, Bruce IN. Correction to: Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the Preclinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort. Arthritis Res Ther. 2021 Oct 19;23(1):263. doi: 10.1186/s13075-021-02645-1. PMID: 34666823; PMCID: PMC8524988.
Copy Download .nbib Format: NLM
Progression from subclinical inflammation to overt SpA in first degree relatives of SpA patients is associated with HLA-B27: the Pre-SpA cohort.

Arthritis care & research

de Jong HMY, de Winter JJH, van der Horst-Bruinsma IE, van Schaardenburg DJ, van Gaalen FA, van Tubergen AM, Weel AEAM, Landewé RBM, Baeten DLP, van de Sande MGH.
PMID: 34219406
Arthritis Care Res (Hoboken). 2021 Jul 05; doi: 10.1002/acr.24743. Epub 2021 Jul 05.

OBJECTIVES: As first-degree relatives (FDRs) of HLA-B27-positive axial spondyloarthritis (axSpA) patients have an increased risk of developing axSpA, the objectives were 1) to evaluate presence of highly specific imaging features as well as clinical signs of SpA at baseline...

Cite
de Jong HMY, de Winter JJH, van der Horst-Bruinsma IE, et al. Progression from subclinical inflammation to overt SpA in first degree relatives of SpA patients is associated with HLA-B27: the Pre-SpA cohort. Arthritis Care Res (Hoboken). 2021;doi: 10.1002/acr.24743.
de Jong, H. M. Y., de Winter, J. J. H., van der Horst-Bruinsma, I. E., van Schaardenburg, D. J., van Gaalen, F. A., van Tubergen, A. M., Weel, A. E. A. M., Landewé, R. B. M., Baeten, D. L. P., & van de Sande, M. G. H. (2021). Progression from subclinical inflammation to overt SpA in first degree relatives of SpA patients is associated with HLA-B27: the Pre-SpA cohort. Arthritis care & research, . https://doi.org/10.1002/acr.24743
de Jong, Henriëtte M Y, et al. "Progression from subclinical inflammation to overt SpA in first degree relatives of SpA patients is associated with HLA-B27: the Pre-SpA cohort." Arthritis care & research vol. (2021). doi: https://doi.org/10.1002/acr.24743
de Jong HMY, de Winter JJH, van der Horst-Bruinsma IE, van Schaardenburg DJ, van Gaalen FA, van Tubergen AM, Weel AEAM, Landewé RBM, Baeten DLP, van de Sande MGH. Progression from subclinical inflammation to overt SpA in first degree relatives of SpA patients is associated with HLA-B27: the Pre-SpA cohort. Arthritis Care Res (Hoboken). 2021 Jul 05; doi: 10.1002/acr.24743. Epub 2021 Jul 05. PMID: 34219406.
Copy Download .nbib Format: NLM
Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity.

Seminars in arthritis and rheumatism

Rasch L, Boers M, Lems W, van Schaardenburg D, Proudman S, Hill CL, Duarte C, Kuriya B, Davis B, Hoogland W, Voshaar M, van Tuyl L.
PMID: 34538513
Semin Arthritis Rheum. 2021 Jul 25; doi: 10.1016/j.semarthrit.2021.07.005. Epub 2021 Jul 25.

OBJECTIVE: Patients have identified pain, fatigue and independence as the most important domains that need to be improved to define remission in rheumatoid arthritis (RA). This study identified and validated instruments for these domains and evaluated their added value...

Cite
Rasch L, Boers M, Lems W, et al. Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity. Semin Arthritis Rheum. 2021;doi: 10.1016/j.semarthrit.2021.07.005.
Rasch, L., Boers, M., Lems, W., van Schaardenburg, D., Proudman, S., Hill, C. L., Duarte, C., Kuriya, B., Davis, B., Hoogland, W., Voshaar, M., & van Tuyl, L. (2021). Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity. Seminars in arthritis and rheumatism, . https://doi.org/10.1016/j.semarthrit.2021.07.005
Rasch, L, et al. "Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity." Seminars in arthritis and rheumatism vol. (2021). doi: https://doi.org/10.1016/j.semarthrit.2021.07.005
Rasch L, Boers M, Lems W, van Schaardenburg D, Proudman S, Hill CL, Duarte C, Kuriya B, Davis B, Hoogland W, Voshaar M, van Tuyl L. Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity. Semin Arthritis Rheum. 2021 Jul 25; doi: 10.1016/j.semarthrit.2021.07.005. Epub 2021 Jul 25. PMID: 34538513.
Copy Download .nbib Format: NLM
Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA.

Annals of the rheumatic diseases

Kissel T, van Wesemael TJ, Lundquist A, Kokkonen H, Kawakami A, Tamai M, van Schaardenburg D, Wuhrer M, Huizinga TW, Scherer HU, van der Woude D, Rantapää-Dahlqvist S, Toes REM.
PMID: 34385139
Ann Rheum Dis. 2022 Jan;81(1):141-143. doi: 10.1136/annrheumdis-2021-220841. Epub 2021 Aug 12.

No abstract available.

Cite
Kissel T, van Wesemael TJ, Lundquist A, et al. Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA. Ann Rheum Dis. 2021;81(1):141-143doi: 10.1136/annrheumdis-2021-220841.
Kissel, T., van Wesemael, T. J., Lundquist, A., Kokkonen, H., Kawakami, A., Tamai, M., van Schaardenburg, D., Wuhrer, M., Huizinga, T. W., Scherer, H. U., van der Woude, D., Rantapää-Dahlqvist, S., & Toes, R. E. M. (2022). Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA. Annals of the rheumatic diseases, 81(1), 141-143. https://doi.org/10.1136/annrheumdis-2021-220841
Kissel, Theresa, et al. "Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA." Annals of the rheumatic diseases vol. 81,1 (2022): 141-143. doi: https://doi.org/10.1136/annrheumdis-2021-220841
Kissel T, van Wesemael TJ, Lundquist A, Kokkonen H, Kawakami A, Tamai M, van Schaardenburg D, Wuhrer M, Huizinga TW, Scherer HU, van der Woude D, Rantapää-Dahlqvist S, Toes REM. Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA. Ann Rheum Dis. 2022 Jan;81(1):141-143. doi: 10.1136/annrheumdis-2021-220841. Epub 2021 Aug 12. PMID: 34385139.
Copy Download .nbib Format: NLM
Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis.

Annals of the rheumatic diseases

Wouters F, Maurits MP, van Boheemen L, Verstappen M, Mankia K, Matthijssen XME, Dorjée AL, Emery P, Knevel R, van Schaardenburg D, Toes REM, van der Helm-van Mil AHM.
PMID: 34285049
Ann Rheum Dis. 2022 Jan;81(1):48-55. doi: 10.1136/annrheumdis-2021-220546. Epub 2021 Jul 20.

OBJECTIVES: The human leukocyte antigen-shared epitope (HLA-SE) alleles and smoking are the most prominent genetic and environmental risk factors for rheumatoid arthritis (RA). However, at which pre-arthritis stage (asymptomatic/symptomatic) they exert their effect is unknown. We aimed to determine...

Cite
Wouters F, Maurits MP, van Boheemen L, et al. Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis. Ann Rheum Dis. 2021;81(1):48-55doi: 10.1136/annrheumdis-2021-220546.
Wouters, F., Maurits, M. P., van Boheemen, L., Verstappen, M., Mankia, K., Matthijssen, X. M. E., Dorjée, A. L., Emery, P., Knevel, R., van Schaardenburg, D., Toes, R. E. M., & van der Helm-van Mil, A. H. M. (2022). Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis. Annals of the rheumatic diseases, 81(1), 48-55. https://doi.org/10.1136/annrheumdis-2021-220546
Wouters, Fenne, et al. "Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis." Annals of the rheumatic diseases vol. 81,1 (2022): 48-55. doi: https://doi.org/10.1136/annrheumdis-2021-220546
Wouters F, Maurits MP, van Boheemen L, Verstappen M, Mankia K, Matthijssen XME, Dorjée AL, Emery P, Knevel R, van Schaardenburg D, Toes REM, van der Helm-van Mil AHM. Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis. Ann Rheum Dis. 2022 Jan;81(1):48-55. doi: 10.1136/annrheumdis-2021-220546. Epub 2021 Jul 20. PMID: 34285049; PMCID: PMC7612192.
Copy Download .nbib Format: NLM
Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis.

Annals of the rheumatic diseases

Wouters F, Maurits MP, van Boheemen L, Verstappen M, Mankia K, Matthijssen XME, Dorjée AL, Emery P, Knevel R, van Schaardenburg D, Toes REM, van der Helm-van Mil AHM.
PMID: 34285049
Ann Rheum Dis. 2022 Jan;81(1):48-55. doi: 10.1136/annrheumdis-2021-220546. Epub 2021 Jul 20.

OBJECTIVES: The human leukocyte antigen-shared epitope (HLA-SE) alleles and smoking are the most prominent genetic and environmental risk factors for rheumatoid arthritis (RA). However, at which pre-arthritis stage (asymptomatic/symptomatic) they exert their effect is unknown. We aimed to determine...

Cite
Wouters F, Maurits MP, van Boheemen L, et al. Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis. Ann Rheum Dis. 2021;81(1):48-55doi: 10.1136/annrheumdis-2021-220546.
Wouters, F., Maurits, M. P., van Boheemen, L., Verstappen, M., Mankia, K., Matthijssen, X. M. E., Dorjée, A. L., Emery, P., Knevel, R., van Schaardenburg, D., Toes, R. E. M., & van der Helm-van Mil, A. H. M. (2022). Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis. Annals of the rheumatic diseases, 81(1), 48-55. https://doi.org/10.1136/annrheumdis-2021-220546
Wouters, Fenne, et al. "Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis." Annals of the rheumatic diseases vol. 81,1 (2022): 48-55. doi: https://doi.org/10.1136/annrheumdis-2021-220546
Wouters F, Maurits MP, van Boheemen L, Verstappen M, Mankia K, Matthijssen XME, Dorjée AL, Emery P, Knevel R, van Schaardenburg D, Toes REM, van der Helm-van Mil AHM. Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis. Ann Rheum Dis. 2022 Jan;81(1):48-55. doi: 10.1136/annrheumdis-2021-220546. Epub 2021 Jul 20. PMID: 34285049.
Copy Download .nbib Format: NLM
Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity.

Seminars in arthritis and rheumatism

Rasch L, Boers M, Lems W, van Schaardenburg D, Proudman S, Hill CL, Duarte C, Kuriya B, Davis B, Hoogland W, Voshaar M, van Tuyl L.
PMID: 34538513
Semin Arthritis Rheum. 2021 Dec;51(6):1360-1369. doi: 10.1016/j.semarthrit.2021.07.005. Epub 2021 Jul 25.

OBJECTIVE: Patients have identified pain, fatigue and independence as the most important domains that need to be improved to define remission in rheumatoid arthritis (RA). This study identified and validated instruments for these domains and evaluated their added value...

Cite
Rasch L, Boers M, Lems W, et al. Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity. Semin Arthritis Rheum. 2021;51(6):1360-1369doi: 10.1016/j.semarthrit.2021.07.005.
Rasch, L., Boers, M., Lems, W., van Schaardenburg, D., Proudman, S., Hill, C. L., Duarte, C., Kuriya, B., Davis, B., Hoogland, W., Voshaar, M., & van Tuyl, L. (2021). Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity. Seminars in arthritis and rheumatism, 51(6), 1360-1369. https://doi.org/10.1016/j.semarthrit.2021.07.005
Rasch, L, et al. "Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity." Seminars in arthritis and rheumatism vol. 51,6 (2021): 1360-1369. doi: https://doi.org/10.1016/j.semarthrit.2021.07.005
Rasch L, Boers M, Lems W, van Schaardenburg D, Proudman S, Hill CL, Duarte C, Kuriya B, Davis B, Hoogland W, Voshaar M, van Tuyl L. Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity. Semin Arthritis Rheum. 2021 Dec;51(6):1360-1369. doi: 10.1016/j.semarthrit.2021.07.005. Epub 2021 Jul 25. PMID: 34538513.
Copy Download .nbib Format: NLM
Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals.

Arthritis & rheumatology (Hoboken, N.J.)

Kroese JM, Brandt BW, Buijs MJ, Crielaard W, Lobbezoo F, Loos BG, van Boheemen L, van Schaardenburg D, Zaura E, Volgenant CMC.
PMID: 33949151
Arthritis Rheumatol. 2021 Nov;73(11):1986-1993. doi: 10.1002/art.41780. Epub 2021 Sep 27.

OBJECTIVE: It has been suggested that rheumatoid arthritis (RA) may originate at the oral mucosa. The aim of the present study was to assess the oral microbiome and periodontal condition in patients with early RA and individuals at risk...

Cite
Kroese JM, Brandt BW, Buijs MJ, et al. Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals. Arthritis Rheumatol. 2021;73(11):1986-1993doi: 10.1002/art.41780.
Kroese, J. M., Brandt, B. W., Buijs, M. J., Crielaard, W., Lobbezoo, F., Loos, B. G., van Boheemen, L., van Schaardenburg, D., Zaura, E., & Volgenant, C. M. C. (2021). Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals. Arthritis & rheumatology (Hoboken, N.J.), 73(11), 1986-1993. https://doi.org/10.1002/art.41780
Kroese, Johanna M, et al. "Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals." Arthritis & rheumatology (Hoboken, N.J.) vol. 73,11 (2021): 1986-1993. doi: https://doi.org/10.1002/art.41780
Kroese JM, Brandt BW, Buijs MJ, Crielaard W, Lobbezoo F, Loos BG, van Boheemen L, van Schaardenburg D, Zaura E, Volgenant CMC. Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals. Arthritis Rheumatol. 2021 Nov;73(11):1986-1993. doi: 10.1002/art.41780. Epub 2021 Sep 27. PMID: 33949151; PMCID: PMC8596438.
Copy Download .nbib Format: NLM
Effectiveness and cost-effectiveness of longstanding exercise therapy versus usual care in patients with axial spondyloarthritis or rheumatoid arthritis and severe limitations: The protocols of two parallel randomized controlled trials.

Physiotherapy research international : the journal for researchers and clinicians in physical therapy

van Wissen MAT, Teuwen MMH, van den Ende CHM, Vliet Vlieland TPM, den Broeder AA, van den Hout WB, Peter WF, van Schaardenburg D, van Tubergen AM, Gademan MGJ, van Weely SFE.
PMID: 34780107
Physiother Res Int. 2021 Nov 15;e1933. doi: 10.1002/pri.1933. Epub 2021 Nov 15.

OBJECTIVES: Research on effectiveness and cost-effectiveness of longstanding exercise therapy in patients with axial SpondyloArthritis (axSpA) or Rheumatoid Arthritis (RA) is scarce, and mainly concerned patients with a relatively favorable health status. We aim to evaluate the effectiveness and...

Cite
van Wissen MAT, Teuwen MMH, van den Ende CHM, et al. Effectiveness and cost-effectiveness of longstanding exercise therapy versus usual care in patients with axial spondyloarthritis or rheumatoid arthritis and severe limitations: The protocols of two parallel randomized controlled trials. Physiother Res Int. 2021;e1933doi: 10.1002/pri.1933.
van Wissen, M. A. T., Teuwen, M. M. H., van den Ende, C. H. M., Vliet Vlieland, T. P. M., den Broeder, A. A., van den Hout, W. B., Peter, W. F., van Schaardenburg, D., van Tubergen, A. M., Gademan, M. G. J., & van Weely, S. F. E. (2021). Effectiveness and cost-effectiveness of longstanding exercise therapy versus usual care in patients with axial spondyloarthritis or rheumatoid arthritis and severe limitations: The protocols of two parallel randomized controlled trials. Physiotherapy research international : the journal for researchers and clinicians in physical therapy, e1933. https://doi.org/10.1002/pri.1933
van Wissen, Maria A T, et al. "Effectiveness and cost-effectiveness of longstanding exercise therapy versus usual care in patients with axial spondyloarthritis or rheumatoid arthritis and severe limitations: The protocols of two parallel randomized controlled trials." Physiotherapy research international : the journal for researchers and clinicians in physical therapy vol. (2021): e1933. doi: https://doi.org/10.1002/pri.1933
van Wissen MAT, Teuwen MMH, van den Ende CHM, Vliet Vlieland TPM, den Broeder AA, van den Hout WB, Peter WF, van Schaardenburg D, van Tubergen AM, Gademan MGJ, van Weely SFE. Effectiveness and cost-effectiveness of longstanding exercise therapy versus usual care in patients with axial spondyloarthritis or rheumatoid arthritis and severe limitations: The protocols of two parallel randomized controlled trials. Physiother Res Int. 2021 Nov 15;e1933. doi: 10.1002/pri.1933. Epub 2021 Nov 15. PMID: 34780107.
Copy Download .nbib Format: NLM
Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis.

Annals of the rheumatic diseases

Wouters F, Maurits MP, van Boheemen L, Verstappen M, Mankia K, Matthijssen XME, Dorjée AL, Emery P, Knevel R, van Schaardenburg D, Toes REM, van der Helm-van Mil AHM.
PMID: 34285049
Ann Rheum Dis. 2022 Jan;81(1):48-55. doi: 10.1136/annrheumdis-2021-220546. Epub 2021 Jul 20.

OBJECTIVES: The human leukocyte antigen-shared epitope (HLA-SE) alleles and smoking are the most prominent genetic and environmental risk factors for rheumatoid arthritis (RA). However, at which pre-arthritis stage (asymptomatic/symptomatic) they exert their effect is unknown. We aimed to determine...

Cite
Wouters F, Maurits MP, van Boheemen L, et al. Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis. Ann Rheum Dis. 2021;81(1):48-55doi: 10.1136/annrheumdis-2021-220546.
Wouters, F., Maurits, M. P., van Boheemen, L., Verstappen, M., Mankia, K., Matthijssen, X. M. E., Dorjée, A. L., Emery, P., Knevel, R., van Schaardenburg, D., Toes, R. E. M., & van der Helm-van Mil, A. H. M. (2022). Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis. Annals of the rheumatic diseases, 81(1), 48-55. https://doi.org/10.1136/annrheumdis-2021-220546
Wouters, Fenne, et al. "Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis." Annals of the rheumatic diseases vol. 81,1 (2022): 48-55. doi: https://doi.org/10.1136/annrheumdis-2021-220546
Wouters F, Maurits MP, van Boheemen L, Verstappen M, Mankia K, Matthijssen XME, Dorjée AL, Emery P, Knevel R, van Schaardenburg D, Toes REM, van der Helm-van Mil AHM. Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis. Ann Rheum Dis. 2022 Jan;81(1):48-55. doi: 10.1136/annrheumdis-2021-220546. Epub 2021 Jul 20. PMID: 34285049.
Copy Download .nbib Format: NLM
A phase-ii study testing weekly platinum derivative combination chemotherapy as 2nd-line treatment in patients with advanced small-cell lung-cancer.

International journal of oncology

Sculier J, Thiriaux J, Bureau G, Lafitte J, Recloux P, Brohee D, Berchier M, Sergysels R, Mommen P, Paesmans M, Klastersky J, Lecomte J, Vanschaardenburg C, Richard V, Diana D, Fortin F, Tagnon A, Kustner U.
PMID: 21556555
Int J Oncol. 1995 Feb;6(2):425-9. doi: 10.3892/ijo.6.2.425.

A phase II trial was conducted to determine the effectiveness of weekly administration of cisplatin (25 mg/m(2) on day 1) and carboplatin (100 mg/m(2) on day 1) as salvage chemotherapy for patients with small cell lung cancer after first-line...

Cite
Sculier J, Thiriaux J, Bureau G, et al. A phase-ii study testing weekly platinum derivative combination chemotherapy as 2nd-line treatment in patients with advanced small-cell lung-cancer. Int J Oncol. 1995;6(2):425-9doi: 10.3892/ijo.6.2.425.
Sculier, J., Thiriaux, J., Bureau, G., Lafitte, J., Recloux, P., Brohee, D., Berchier, M., Sergysels, R., Mommen, P., Paesmans, M., Klastersky, J., Lecomte, J., Vanschaardenburg, C., Richard, V., Diana, D., Fortin, F., Tagnon, A., & Kustner, U. (1995). A phase-ii study testing weekly platinum derivative combination chemotherapy as 2nd-line treatment in patients with advanced small-cell lung-cancer. International journal of oncology, 6(2), 425-9. https://doi.org/10.3892/ijo.6.2.425
Sculier, J, et al. "A phase-ii study testing weekly platinum derivative combination chemotherapy as 2nd-line treatment in patients with advanced small-cell lung-cancer." International journal of oncology vol. 6,2 (1995): 425-9. doi: https://doi.org/10.3892/ijo.6.2.425
Sculier J, Thiriaux J, Bureau G, Lafitte J, Recloux P, Brohee D, Berchier M, Sergysels R, Mommen P, Paesmans M, Klastersky J, Lecomte J, Vanschaardenburg C, Richard V, Diana D, Fortin F, Tagnon A, Kustner U. A phase-ii study testing weekly platinum derivative combination chemotherapy as 2nd-line treatment in patients with advanced small-cell lung-cancer. Int J Oncol. 1995 Feb;6(2):425-9. doi: 10.3892/ijo.6.2.425. PMID: 21556555.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 24 entries